量化接种前滴度和疫苗接种史对流感疫苗免疫原性的影响
该研究采用多季节队列数据与统一分析框架,建立灵活的个体水平贝叶斯模型,估计接种前HAI滴度、年龄、性别、疫苗接种史和研究现场等宿主因素与疫苗诱导的HAI滴度抗体提升和衰减之间的关联及交互作用,并应用于A(H1N1)和A(H3N2)亚型。研究发现接种后HAI滴度动态显著受接种前HAI滴度和疫苗接种史影响,接种前HAI滴度较低者血清保护持续时间更长。
要点
- 接种后HAI滴度动态显著受接种前HAI滴度和疫苗接种史影响。
- 接种前HAI滴度较低者,血清保护(HAI滴度≥1:40)持续时间更长。
- 细胞培养A(H1N1)疫苗中,接种前HAI滴度1:10和1:20时,接种不频繁者较频繁者血清保护持续时间分别长171天和159天。
核心结论
- 接种后HAI滴度动态显著受接种前HAI滴度和疫苗接种史影响,接种前HAI滴度较低者血清保护持续时间更长。
- 未来依赖血清学终点的研究应纳入接种前HAI滴度和既往疫苗接种状态对血清阳性和血清转化估计的影响,因为这些因素可显著影响个体接种后抗体动力学。
研究设计与样本
- 研究结合多个季节开展的队列研究中的宿主因素和疫苗诱导的宿主体内抗体动力学,采用统一分析框架。
- 开发了灵活的个体水平贝叶斯模型,用于估计宿主因素(包括接种前HAI滴度、年龄、性别、疫苗接种史和研究现场)与疫苗诱导的HAI滴度抗体提升和衰减之间的关联及交互作用。
主要发现
- 接种后HAI滴度动态显著受接种前HAI滴度和疫苗接种史影响,接种前HAI滴度较低者血清保护(HAI滴度等于1:40或更高)持续时间更长。
- 疫苗接种史对蛋培养A(H1N1)疫苗株抗体提升的影响在接种前HAI滴度较高个体中更强,而该效应在蛋培养A(H3N2)疫苗株中减弱。
- 对于细胞培养A(H1N1),接种前HAI滴度为1:10时,接种不频繁者(过去五年内接种少于2剂)预期的接种后血清保护持续时间比频繁接种者(过去五年内接种2剂或更多)长171天(95% PPI 128-220);接种前HAI滴度为1:20时,相应延长159天(95% PPI 120-200)。
- 研究发现描述A(H1N1)细胞培养株个体水平血清保护持续时间的经验分布存在显著差异。
临床怎么用
- 作者认为,未来依赖血清学终点的研究应纳入接种前HAI滴度和既往疫苗接种状态对血清阳性和血清转化估计的影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Epidemiological studies suggest that heterogeneity in influenza vaccine antibody response can be associated with specific host factors, including pre-vaccination immune status, age, gender, and vaccination history. However, the pattern of reported associations varies between studies. To better understand the underlying influences on antibody responses, we combined host factors and vaccine-induced in-host antibody kinetics from a cohort study conducted across multiple seasons with a unified analysis framework. We developed a flexible individual-level Bayesian model to estimate associations and interactions between host factors, including pre-vaccine HAI titre, age, sex, vaccination history and study setting, and vaccine-induced HAI titre antibody boosting and waning. We applied the model to derive population-level and individual effects of post-vaccine antibody kinetics for A(H1N1) and A(H3N2) influenza subtypes. We found that post-vaccine HAI titre dynamics were significantly influenced by pre-vaccination HAI titre and vaccination history and that lower pre-vaccination HAI titre results in longer durations of seroprotection (HAI titre equal to 1:40 or higher). We also observed that the effect of vaccination history on antibody boosting was stronger for egg-grown A(H1N1) vaccinating strains in individuals with higher pre-vaccination HAI titres, whereas this effect diminished for egg-grown A(H3N2) vaccinating strains. Consequently, for cell-grown A(H1N1), our inference finds that the expected duration of seroprotection post-vaccination was 171 (95 % Posterior Predictive Interval[PPI] 128-220) and 159 (95 % PPI 120-200) days longer for those who are infrequently vaccinated (<2 vaccines in last five years) compared to those who are frequently vaccinated (2 or more vaccines in the last five years) at pre-vaccination HAI titre values of 1:10 and 1:20 respectively. In addition, we found significant differences in the empirical distributions that describe the individual-level duration of seroprotection for A(H1N1) cell-grown strains. In future, studies that rely on serological endpoints should include the impact of pre-vaccine HAI titre and prior vaccination status on seropositivity and seroconversion estimates, as these can significantly influence an individual's post-vaccination antibody kinetics.
引用
- Hodgson D, Sánchez-Ovando S, Carolan L, et al. Quantifying the impact of pre-vaccination titre and vaccination history on influenza vaccine immunogenicity. Vaccine. 2024. PMID: 39638659. doi:10.1016/j.vaccine.2024.126579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。